APTX

NYX-2925

Neuropathic Pain Associated with Diabetic Peripheral Neuropathy

Stage (next event)

Expected Date

Phase 2 Readout

H1 2022

Catalyst Info & Data Links

TITLE: NYX-2925 for Neuropathic Pain Associated with Diabetic Peripheral Neuropathy Phase 2 Readout

  • Clinical Trial (NCT04146896) Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy (DPN)


WHAT IS THE NEXT CATALYST EVENT?

  • Phase 2 to be initiated


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • H1 2022


PRIOR DATA/EVENTS

PRESS RELEASES

Mechanism of Action

MECHANISM OF ACTION

  • NMDA receptors are critically important in normal brain and nervous system function and play a key role in regulating how neurons connect to each other. The activation and opening of NMDA receptors, in response to the binding of specific neurotransmitters including glutamate, triggers a cascade of events that results in synaptic plasticity. This activation may be a beneficial therapeutic approach to treating disorders of the brain and nervous system.

Updated by MV

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon